Literature DB >> 16160616

Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients.

Karin Fehsel1, Stefan Loeffler, Klaus Krieger, Uwe Henning, Markus Agelink, Victoria Kolb-Bachofen, Ansgar Klimke.   

Abstract

The present study examined cellular effects of the atypical antipsychotic drug clozapine on blood cells of treated patients with and without clozapine-induced agranulocytosis (CA). Blood from one patient who commenced clozapine treatment was examined at weekly intervals for 128 days. Olanzapine-treated (n = 5) and polymedicated (n = 14) schizophrenic patients, as well as healthy subjects (n = 19) and septic shock patients (n = 8), were studied for comparison. We observed dramatically increased numbers of native neutrophils stained for superoxide anion production (P < or = 0.005, n = 10) and significantly elevated expression levels of the proapoptotic genes p53 (P < or = 0.020), bax alpha (P < or = 0.001), and bik (P < or = 0.002) in all tested non-CA patients (n = 19) and CA patients (n = 4). In non-CA patients, the expression of these genes did not correlate to the percentage of apoptotic neutrophils (2.0% +/- 1.3%), but in CA patients about 37% of the neutrophils show morphologic signs of apoptosis (P < or = 0.001). Under G-CSF therapy of CA, the number of apoptotic neutrophils and the expression of the proapoptotic genes decreased significantly. In conclusion, high production of reactive oxygen species in neutrophils of clozapine-treated patients, together with increased expression of proapoptotic genes, suggests that neutrophils are predisposed to apoptosis in schizophrenic patients under clozapine therapy. The correlation between drug and proapoptotic markers was highest for clozapine and bax alpha as well as superoxide anion radicals. This indicates oxidative mitochondrial stress in neutrophils of clozapine-treated patients which probably contributes to the induction of apoptosis and sudden loss of neutrophils and their precursors in CA patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160616     DOI: 10.1097/01.jcp.0000177668.42640.fe

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  14 in total

1.  Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.

Authors:  K van der Weide; H Loovers; K Pondman; J Bogers; T van der Straaten; E Langemeijer; D Cohen; J Commandeur; J van der Weide
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

2.  Leukocytosis after Clozapine Treatment in a Patient with Chronic Schizophrenia.

Authors:  Aslıhan Polat; Uğur Çakir; Nermin Gündüz
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

Review 3.  Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma.

Authors:  Nazife Gamze Usta; Cana Aksoy Poyraz; Melih Aktan; Alaattin Duran
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

4.  Effect of in utero exposure to the atypical anti-psychotic risperidone on histopathological features of the rat placenta.

Authors:  K P Singh; Manoj K Singh; Shrikant Gautam
Journal:  Int J Exp Pathol       Date:  2016-06-03       Impact factor: 1.925

5.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 6.  Effect of atypical antipsychotics on fetal growth: is the placenta involved?

Authors:  Sandeep Raha; Valerie H Taylor; Alison C Holloway
Journal:  J Pregnancy       Date:  2012-07-11

7.  Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells.

Authors:  Verόnica Contreras-Shannon; Dylan L Heart; R Madelaine Paredes; Erica Navaira; Gabriel Catano; Shivani Kaushal Maffi; Consuelo Walss-Bass
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

8.  Homocysteine levels in patients with schizophrenia on clozapine monotherapy.

Authors:  Adam Wysokiński; Iwona Kłoszewska
Journal:  Neurochem Res       Date:  2013-07-20       Impact factor: 3.996

9.  A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.

Authors:  Marilena Gilca; Gabriela Piriu; Laura Gaman; Corina Delia; Liviu Iosif; Valeriu Atanasiu; Irina Stoian
Journal:  Psychopharmacology (Berl)       Date:  2014-05-29       Impact factor: 4.530

10.  Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature.

Authors:  Aakanksha Singh; Sandeep Grover; Pankaj Malhotra; Subhash C Varma
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.